Whatever happened to the stroke test,was it shelved???? |
Would PRM be interested in buying any "cheap "asset of Oncimmune from The Administrator ? |
From stockinvest:
The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 24.08% during the next 3 months and, with a 90% probability hold a price between 4.37p and 6.96p at the end of this 3-month period. |
Anyone want to own up to Zico.?? |
Looks like the overhang has finally been cleared.
Price being quoted to buy 150,000 is 4.6231p
For 200,000 it's 4.70p and it's NT for above 200,000. |
Two large trades ( buys ) of 243,000 and 275,000 today.
The over hang ( sells after the contract news ) has been reduced slightly further after these buys today.
Once this overhang is cleared , the share price will RISE achieving new highs for 2025. |
Due to the strong growth the company has been experiencing over the last 6 months and the expected growth over the coming 12 months and the share price will continue to RISE throughout the current financial year and will most likely be North of 10p by the end of 2025 and will RISE even further next year. |
Thanks Z1CO,sounds good.
W41 |
W41
The whole of proteomics market including mass spectrometry is experiencing huge growth
Proteome Sciences is nicely poised to grow it's revenues and profits for the foreseeable future.
Share price will continue to rerate massively over the short , medium and long term.
Your target of 6p will be achieved in about 4 to 6 weeks , definitely before the end of April. |
Z1CO - I tend to agree with you that the opportunity for PRM may be ‘now’! However I’m waiting to read the forward looking statement with the results before I get too excited.
Whatever the outlook I am expecting the shares to finish north of my initial 6p target by Y/E, how much north who knows!
W41 |
Thanks Saad
After the strong H2 , 2024 will be a much improved over 2023 but the real growth will be in the current year to 31/12/2025.
Once this is confirmed the share price will rerate massively from the current levels.
I'm looking forward to the results. |
Good posting zico
Indeed prospects do look very good for 2025 and 2026 , with many orders already carried over into 2026 and more to come.
Price will take off again once the company gives a further update. |
The big question remains how good was H2 to 31/12/2024
In a strongly worded trading update in December , quote the substantial increase in services orders required the company to acquire two additional top-end mass spectrometers that came on stream during the year to provide additional capacity but these are still not enough to satisfy the current demand in the pipeline that has extended out to 2026 from additional customer contracts that have been secured.
I expect revenue for H2 to be around £3.5m giving a full year revenue of £5.72m.
The real growth will occur in the current year to 31/12/2025 with revenue likely to exceed £8m.
Share price having consolidated at above 4p will rerate substantially higher over the coming months. |
Full year results hopefully by the end of this month or early April will provide more info regarding how the company is gaining traction in this field. |
Single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes.
Single cell proteomics has been identified as a game-changer in drug discovery, with Proteome Sciences well positioned in this field. By analysing individual cells' protein profiles, it helps pinpoint precise disease-associated proteins and potential drug targets within heterogeneous populations. This technology enhances personalised medicine, streamlines preclinical studies, and increases the likelihood of successful drug development by providing detailed insights into the molecular intricacies of diseases and drug actions. |
 The company launched SysQuant® SCP, a commercial service for single cell proteomics
SysQuant® SCP is supported by Proteome’s TMTpro™ isobaric labelling reagents and can identify more than 1,000 proteins in each study of 576 single cells which allows researchers to gain insights into the biology and heterogeneity of individual cells. This can be crucial in understanding complex diseases and identifying potential therapeutic targets. This sits in contrast with traditional methods which typically analyse bulk populations of cells, masking the heterogeneity that may exist among individual cells.
Proteome Sciences' single cell proteomics services are expected to significantly improve the performance of drug development across multiple disease areas including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders.
The SysQuant® SCP pipeline analyses mass spectrometry data, uncovering subtle changes in individual cells and sub-populations of the same cell type. This data enhances understanding of heterogeneity and disease evolution, leading to new targets for personalised medicine. |
Single cell proteomics;
The company said in December 2024 it is processing its first commercial orders in single cell proteomics (SCP). |
Outlook in September
Over the last two years we invested substantially to expand our business by establishing the facility in San Diego, developing new ranges of TMT®, plex DIA tags and Single Cell Proteomics (SCP) to address the future growing global demand for proteomics applications.
For our tag business we expect the recent introduction of the TMTpro™ 35plex tags to generate strong revenues in the coming years. Licensing discussions have been initiated for our plexDIA tags from which new and additional revenue streams will be generated. |
There has been a strong resurgence in TMT orders and revenues in the second half of the year that should result in full year expectations for revenues to be considerably higher than in 2023.
TMT® sales, and royalties in 2023 was £3.40m , so according to management revenue in 2024 will be considerably HIGHER.
The current financial year to 31/12/2025 will be a lot better than 2024 , when this is confirmed it will drive the share price substantially higher from the current levels. |
Share price poised to rerate massively after the full year results and the outlook for 2025.
From the interim results:
TMT®
First half-year revenue from the TMT license with Thermo Scientific declined to £1.85m (2023: £2.20m). We believe this largely resulted from customers holding off their orders for TMT tags in anticipation of the release of the new generation TMT 32plex and TMT pro 35plex tags at the ASMS meeting in June. After very positive feedback and the tags available thereafter, there has been a strong resurgence in TMT orders and revenues in the second half of the year that should result in full year expectations for revenues to be considerably higher than in 2023. We continuously monitor our stock levels of all TMT® and TMTpro™ reagents to ensure we can meet forecast demands for the foreseeable future. |
250,000 buy @ 4.30p gone through. |
I managed to get some more on the unexpected pullback yesterday.
The company is currently experiencing strong trading , share price is still 50% less than what it was in 2023.
Shares will rebound strongly in 2025. |
You may well be right, I was merely adding some information that I thought relevant.
Although you would have thought that one would follow the other if that were the case. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
